

In the Claims:

Claims 1-24 (Cancelled)

25. (Currently Amended): An isolated, recombinant polypeptide comprising a member selected from the group consisting of

- (a) ~~the an amino acid sequence SEQ ID NO:2 matching one of SEQ ID NOS:2 or 4;~~
- (b) ~~an immunogenic polypeptide comprising a fragment sequence of at least contiguous 15 amino acids of SEQ ID NO:2 that matches an aligned contiguous segment of one of SEQ ID NOS:2 or 4;~~

wherein the immunogenic fragment isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the to-a polypeptide SEQ ID NO:2 having the sequence of one of SEQ ID NOS:2 or 4.

26. (Cancelled)

27. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (a).

28. (Cancelled)

29. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (b).

30. (Cancelled)

31. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the isolated polypeptide, when administered to a subject in a suitable composition which

can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

32. (Currently Amended): The isolated, recombinant polypeptide of Claim 25 wherein the isolated, recombinant polypeptide of (a) consists of SEQ ID NO:2 one of SEQ ID NOS: 2 or 4.

Claims 33-34 (Cancelled)

35. (Currently Amended): A fusion protein comprising the isolated, recombinant polypeptide of Claim 25.

Claims 36-39 (Cancelled)

40. (Currently Amended): An immunogenic composition A vaccine comprising the isolated, recombinant polypeptide of Claim 25 and a pharmaceutically acceptable carrier.

41. (Currently Amended): The immunogenic composition of Claim 40, wherein the immunogenic composition vaccine comprises at least one other *Moraxella catarrhalis* antigen in addition to the antigen provided by the isolated recombinant polypeptide.

42. (Cancelled)

43. (Currently Amended): A method for inducing an immune response in a mammal comprising administration of the isolated, recombinant polypeptide of Claim 25.

Claims 44-46 (Cancelled)

47. (New): A fusion protein comprising the isolated, recombinant polypeptide of Claim 27.

48. (New): A fusion protein comprising the isolated, recombinant polypeptide of Claim 29.

49. (New): An immunogenic composition comprising the isolated, recombinant polypeptide of claim 27.

50. (New): An immunogenic composition comprising the isolated, recombinant polypeptide of claim 29.

51. (New): An isolated polypeptide consisting of SEQ ID NO:2.